Agenus Inc. (AGEN) – What Are Analysts Thinking About This Stock?

Shares of Agenus Inc. (NASDAQ:AGEN) have earned a consensus rating of “Moderate Buy” from the six research firms that are currently covering the firm, Marketbeat reports. Two analysts have rated the stock with a hold rating and four have issued a buy rating on the company. The average 12 month price objective among brokerages that have issued ratings on the stock in the last year is $25.00.

Several equities analysts have commented on the stock. Rodman & Renshaw initiated coverage on shares of Agenus in a research note on Monday, September 28th. They issued a “buy” rating and a $19.00 price target for the company. Wall Street Zen lowered shares of Agenus from a “strong-buy” rating to a “hold” rating in a research note on Monday, August 17th. Weiss Ratings raised shares of Agenus from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Monday. HC Wainwright reaffirmed a “buy” rating and set a $25.00 price objective (down from $30.00) on shares of Agenus in a research report on Tuesday, August 11th. Finally, B. Riley Financial restated a “buy” rating and issued a $16.00 price target (up from $14.00) on shares of Agenus in a research note on Monday.

Institutional Investors Weigh In On Agenus

Several hedge funds and other institutional investors have recently bought and sold shares of AGEN. Globeflex Capital L P acquired a new position in Agenus during the second quarter worth approximately $1,281,000. Bank of America Corp DE grew its holdings in shares of Agenus by 796.7% during the first quarter. Bank of America Corp DE now owns 118,782 shares of the biotechnology company’s stock worth $397,000 after buying an additional 105,536 shares during the last quarter. Bank of New York Mellon Corp acquired a new position in Agenus in the 2nd quarter valued at about $311,000. HighTower Advisors LLC purchased a new stake in Agenus during the 3rd quarter valued at approximately $574,000. Finally, State of Wyoming acquired a new stake in Agenus during the 3rd quarter worth approximately $225,000. 61.46% of the stock is currently owned by institutional investors and hedge funds.

Agenus Price Performance

Shares of NASDAQ AGEN opened at $7.22 on Friday. The company has a market capitalization of $326.70 million, a P/E ratio of 10.94 and a beta of 1.53. The company has a 50 day simple moving average of $7.42 and a 200-day simple moving average of $5.06. Agenus has a 1 year low of $2.71 and a 1 year high of $10.31.

Agenus (NASDAQ:AGEN) last posted its earnings results on Thursday, November 5th. The biotechnology company reported $0.02 EPS for the quarter, beating analysts’ consensus estimates of ($0.28) by $0.30. The company had revenue of $31.49 million for the quarter, compared to analysts’ expectations of $28.20 million. Agenus had a net margin of 22.10% and a negative return on equity of 27.16%. As a group, research analysts expect that Agenus will post -0.23 EPS for the current year.

About Agenus

Agenus Inc. is a biotechnology company focused on developing immunotherapies for cancer. Its research and development programs use approaches such as antibody treatments, cancer vaccines, immune-system adjuvants and cell therapies. The company’s clinical-stage pipeline includes botensilimab, an investigational anti-CTLA-4 antibody, and balstilimab, an investigational anti-PD-1 antibody. Agenus is studying these therapies, including in combination, for potential use against several types of cancer.